Impact of body composition on clinical outcomes in metastatic renal cell cancer.
Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada. patricia.tang@albertahealthservices.ca
Patricia A
PA
Tang
Daniel Y C
DY
Heng
Toni K
TK
Choueiri
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D009765:Obesity / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A